Summary: In 2025, the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) published an update of their guidelines for the management of dyslipidaemia, focusing primarily on selected aspects of cardiovascular risk assessment and emerging therapeutic options. Despite these modifications, the fundamental goals of treatment remain unchanged, with effective lowering of low-density lipoprotein cholesterol continuing to be the primary therapeutic objective. With regard to hypertriglyceridaemia, statin therapy remains the first-line treatment (except in cases of severe hypertriglyceridaemia), while eicosapentaenoic acid is recommended as a second-line option, and fibrates may be considered as an additional strategy for treatment intensification. This review provides a concise overview of the key aspects of managing atherogenic dyslipidaemia, considering not only the available scientific evidence but also insights derived from routine clinical practice and the position of Polish experts presented in the Fifth Sopot Declaration. Owing to its practical focus, this document takes into account the specific characteristics of the Polish healthcare system and offers guidance on optimizing therapeutic decision-making in patients managed in everyday clinical care settings.